Enterprise Value

4.263B

Cash

412.1M

Avg Qtr Burn

-127.2M

Short % of Float

5.89%

Insider Ownership

3.60%

Institutional Own.

88.26%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DTX301 Details
Ornithine transcarbmylase deficiency

Phase 3

Update

DTX401 Details
Glycogen Storage Disease Type Ia

Phase 3

Update

GTX-102 Details
Angelman Syndrome

Phase 3

Initiation

UX143 (Setrusumab) Details
Osteogenesis imperfecta

Phase 2/3

Update

UX053 Details
Rare diseases, glycogen storage disease type III

Phase 1/2

Data readout

UX701 Details
Wilson's disease, Rare diseases

Phase 1/2

Data readout

UX111 (ABO-102) Details
Rare diseases, Sanfilippo Syndrome

Phase 1/2

Update